ArticlemedRxiv : the preprint server for health sciences2026
Epigenetic Regulation of Immune Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent and debilitating condition with unclear etiology. Increasing evidence implicates immune dysregulation, yet the molecular mechanisms underlying impaired immune regulation remain poorly defined. This study investigated the role of adaptive immune responses and DNA methylation in CP/CPPS pathogenesis. Methods: Voided bladder 3 (VB3) urine samples from CP/CPPS patients and healthy controls were analyzed for CD4⁺ T cell markers and lineage-defining transcription factors. DNA methylation profiling of peripheral blood mononuclear cells (PBMCs) and purified CD4⁺ T cells was performed using targeted methylation arrays. Functional assays evaluated IL-10 production following lipopolysaccharide (LPS) stimulation, with or without azacitidine (AZA), a DNA methyltransferase inhibitor that reverses methylation-dependent gene silencing. In vivo relevance was assessed using the experimental autoimmune prostatitis (EAP) mouse model. Results: VB3 samples from CP/CPPS patients demonstrated elevated CD4⁺ T cell transcripts with a Th17/Th1 (RORγT⁺/TBET⁺) bias and reduced FOXP3 expression. DNA methylation analysis revealed hypermethylation of IL10 and FOXP3 promoters and hypomethylation of inflammatory genes including CD274, ITGAL, and TNFα. PBMCs from patients exhibited diminished IL-10 secretion in response to LPS, which was restored by azacitidine treatment. In the EAP model, recombinant IL-10 administration failed to attenuate pelvic allodynia, whereas azacitidine significantly reduced pain sensitivity. Conclusions: CP/CPPS is associated with widespread epigenetic reprogramming of immune regulatory genes leading to impaired IL-10-mediated immune regulation. Pharmacologic inhibition of DNA methylation restored IL-10 responses and alleviated pain in vivo, supporting demethylation therapy as a potential strategy for treating chronic prostatic inflammation and pelvic pain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.